Literature DB >> 1621590

[A mechanism for reducing intraocular pressure in normal volunteers using UF-021, a prostaglandin-related compound].

H Tetsuka1, H Tsuchisaka, K Kin, Y Takahashi, M Takase.   

Abstract

The mechanism of reduction of intraocular pressure (IOP) and other ocular effects were studies after topical application of prostaglandin (PG) F2 alpha and UF-021, a new PG related compound, in eight normal volunteers. IOP, aqueous humor flow rate and outflow rate were evaluated during a period of four hours after the application. Both PGF2 alpha and UF-021 caused significant and similar IOP reduction for four hours. Neither compound produced any significant change in the aqueous humor flow rate or outflow rate, suggesting the increase of unconventional outflow rate as being the possible mechanism of IOP reduction in normal human eyes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1621590

Source DB:  PubMed          Journal:  Nippon Ganka Gakkai Zasshi        ISSN: 0029-0203


  5 in total

1.  Effect of topical unoprostone isopropyl on optic nerve head circulation in controls and in normal-tension glaucoma patients.

Authors:  Itaru Kimura; Kei Shinoda; Tomihiko Tanino; Yuichiro Ohtake; Yukihiko Mashima
Journal:  Jpn J Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 2.447

2.  Unoprostone (isopropyl unoprostone)

Authors:  M Haria; C M Spencer
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 3.  A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension.

Authors:  D L Eisenberg; C B Camras
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 4.  Prostaglandin analogues in the treatment of glaucoma.

Authors:  C Lindén; A Alm
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

Review 5.  An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy.

Authors:  Derrick S Fung; Jess T Whitson
Journal:  Clin Ophthalmol       Date:  2014-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.